Monitoring osteoporosis treatment

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 6, 2009, Pages 781-788

  Compston, Juliet ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

biochemical markers of bone turnover; bone mineral density; monitoring; osteoporosis; treatment

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE DERIVATIVE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CHEMICAL ANALYSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMUR NECK FRACTURE; FRACTURE; FRACTURE REDUCTION; HEALTH CARE PERSONNEL; HIP FRACTURE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; HUMANS; OSTEOPOROSIS;

EID: 71849119683     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.09.007     Document Type: Review

References (56)

1. Black D., Cummings S., Karpf D., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing fracture. Lancet 348 (1996) 1535-1541
2. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial. JAMA 282 (1999) 1344-1352
3. Reginster J., Minne H.W., Sorensen O.H., et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
4. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
5. Chesnut C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
6. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
7. Reginster J.Y., Seeman E., de Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90 (2005) 2816-2822
8. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
9. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146 (2007) 326-339
10. Black D.M., Delmas P.D., Eastell R., et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
11. International Society for Clinical Densitometry (ISCD). Official positions. Available at: (2007). www.iscd.org
12. National Osteoporosis Foundation (NOF). New clinicians guide to prevention and treatment of osteoporosis. Available at: (2008). www.nof.org
13. AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9 (2003) 544-564
14. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 (2001) 785-795
15. Brown J.P., Josse R.G., and Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 167 10 Suppl (2002) S1-S34
16. Compston J., Cooper A., Cooper C., and National Osteoporosis Guideline Group. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62 (2009) 105-108
17. Glüer C.C., Blake G., Lu Y., et al. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5 (1995) 262-270
18. Glüer C.C. Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14 (1999) 1952-1962
19. Bonnick S.L., Johnston C.C., Kleerekoper M., et al. Importance of precision in bone density measurements. J Clin Densitom 4 (2001) 105-110
20. Leslie W.D. Factors affecting short-term bone density precision assessment and the effect on patient monitoring. J Bone Miner Res 23 (2008) 199-204
21. Bell K.J., Hayen A., Macaskill P., et al. Is routine monitoring of bone mineral density warranted after initiating bisphosphonate treatment?. Br Med J 26 (2009) 136-142
22. Lindsay R., Pack S., and Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 16 (2005) 306-312
23. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312 (1996) 1254-1259
24. Delmas P.D., and Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or non-vertebral fracture risk with anti-resorptive therapy. Bone 34 (2004) 599-604
25. Delmas P.D., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with anti-resorptive drugs: some issues with meta-analyses. J Bone Miner Res 19 (2004) 33-37
26. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
27. Sarkar S., Mitlak B.H., Wong M., et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
28. Watts N.B., Geusens P., Barton I.P., and Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20 (2005) 2097-2104
29. Chapurlat R.D., Palermo L., Ramsay P., and Cummings S.R. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16 (2005) 842-848
30. McClung M.R., Geusens P., Miller P.D., and Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
31. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
32. Compston J.E., and Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 368 (2006) 973-974
33. Seeman E., Compston J., Adachi J., et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18 (2007) 711-719
34. Huybrechts K.F., Ishak K.J., and Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
35. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
36. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 333 (1995) 1437-1443
37. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
38. Christiansen C., Tanko L.B., Warming L., et al. Dose-dependent effects on bone resorption and formation of intermittently administered ibandronate. Osteoporos Int 14 (2003) 609-613
39. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43 (2008) 222-229
40. Dobnig H., Sipos A., Jiang Y., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90 (2005) 3970-3977
41. Reginster J.Y., Deroisy R., Dougados M., et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomised, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos Int 13 (2002) 925-931
42. Seibel M.J. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26 (2005) 97-122
43. Szulc P., and Delmas P.D. Biochemical markers of bone turnover: potential use in the investigation and management of osteoporosis. Osteoporos Int 19 (2008) 1683-1704
44. Bollen A.M., Martin M.D., Leroux B.G., and Eyre D.R. Circadian variation in urinary excretion of bone collagen cross-links. J Bone Miner Res 22 (1995) 1885-1890
45. Aoshima H., Kushida K., Takahashi M., et al. Circadian variation of urinary type 1 collagen cross-linked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22 (1998) 73-78
46. Schlemmer A., and Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 140 (1999) 332-337
47. Clowes J.A., Hannon R.A., Yap T.S., et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30 (2002) 886-890
48. Stoffel K., Engler H., Kuster M., and Riesen W. Changes in biochemical markers after lower limb fractures. Clin Chem 53 (2007) 131-134
49. Obrant K.J., Ivaska K.K., Gerdhem P., et al. Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 36 (2005) 786-792
50. Bauer D.C., Black D.M., Garnero P., and Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
51. Eastell R., Barton I., Hannon R.A., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
52. Eastell R., Hannon R.A., Garnero P., et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22 (2007) 1656-1660
53. Reginster J.Y., Sarkar S., Zegels B., et al. Reduction in P1NP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
54. Bjarnasson N.H., Sarkar S., Duong T., et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12 (2001) 922-930
55. Clowes J.A., Peel N.F.A., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
56. Delmas P.D., Vrijens B., Eastell R., and Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92 (2007) 1296-1304